Fate Therapeutics Reports First Quarter 2014 Financial Results

We are well-positioned to efficiently advance PROHEMA for the treatment of hematologic malignancies in patients across a wide range of ages, and we remain on track to complete the planned interim analysis of the PUMA study in the second half of 2014," commented .

http://ift.tt/1iQwNlz